AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04450563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day outpatient intervention
Description: The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
Study NCT04450563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day outpatient intervention
Description: The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
Study NCT04229953 — intervention group
Intervention type: DEVICE
Intervention: US scan with 3D/4D VRU software
Description: Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done.
Study NCT01462136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-490 Injection
Description: 7.5 mg/kg single dose administered intravenously over 30 minutes
Study NCT02901496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise Training
Description: Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max
Study NCT02901496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.
Study NCT02901496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Exercise
Description: Control to exercise
Study NCT02901496 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Exercise
Description: Control to exercise
Study NCT02901496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
Study NCT02901496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
Study NCT02901496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
Study NCT00528983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) Azacitidine
Description: 75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
Study NCT00528983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
Study NCT00528983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
Study NCT03137186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
Study NCT03194178 — intervention group
Intervention type: OTHER
Intervention: Pierre Robin sequence patients
Description: 4 questionnaires will be completed by the patient :~* Kidscreen 52 (generic quality of life questionnaire)~* Voice Handicap Index : VHI-9i (specific quality of life questionnaire)~* Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)~* MDI-C (composite depression scale for minors)
Study NCT00268437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
Study NCT00268437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
Study NCT00268437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00268437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00268437 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
Study NCT00525044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Study NCT00525044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01489202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: platinum chromium everolimus-eluting stent
Description: An everolimus-eluting stent with a platinum chromium platform
Study NCT01489202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cobalt chromium everolimus-eluting stent
Description: An everolimus-eluting stent with cobalt chromium platform
Study NCT02036632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Eye Patching
Study NCT01033656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: 100 mg subcutaneous injection daily
Study NCT01033656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparators
Description: po drugs, comparators
Study NCT01704287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT01704287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin per institutional standard
Study NCT01704287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin per institutional standard
Study NCT01704287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel per institutional standard
Study NCT01704287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel per institutional standard
Study NCT01704287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine per institutional standard
Study NCT01704287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine per institutional standard
Study NCT01704287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide per institutional standard
Study NCT01704287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide per institutional standard
Study NCT04100629 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: digital support: text messages
Description: In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
Study NCT04100629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital support: text messages
Description: In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
Study NCT04042740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P)
Description: Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
Study NCT02454335 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy
Description: The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
Study NCT03207113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ned
Description: Prostate cancer survivorship application.
Study NCT02611661 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI
Study NCT02611661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Study NCT01246596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental root planing
Description: The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,\[1\] thus helping to establish a periodontium that is free of disease.\[2\]
Study NCT02611661 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Percutaneous ablation
Study NCT02611661 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Study NCT03700151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment for Children with Severe Speech Sound Disorders
Description: The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
Study NCT03713034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PlayTest!
Description: Participants in the PlayTest! intervention arm played the game on their assigned iPads once per week for an hour over the course of 4-5 weeks.
Study NCT03713034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control games
Description: Participants in the control arm played the games on their assigned iPads once per week for an hour over the course of 4-5 weeks.
Study NCT02722876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contralateral Rehabilitation
Description: Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
Study NCT02722876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo flexibility exercise
Description: Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
Study NCT00617136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative warming (Bair Hugger)
Description: Intraoperative warming
Study NCT00617136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre- and intraoperative warming (HotDog)
Description: Pre- and intraoperative warming by HotDog
Study NCT00617136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative warming (HotDog)
Description: Intraoperative warming
Study NCT00713817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study NCT00713817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
Study NCT03846349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOPI
Description: IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.
Study NCT03846349 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EMT threshold
Description: EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.
Study NCT03420079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-411 Dose-escalation
Description: * FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR.
Study NCT03420079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-411 Dose-expansion
Description: * FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR.
Study NCT03987724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) imaging at rest and during supine bicycle exercise
Description: Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
Study NCT04667910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 601 1.25mg
Description: Solution for injection (intravitreal use)
Study NCT04667910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizuman 0.5 mg
Description: Solution for injection (intravitreal use)
Study NCT02863731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating working postures, first day
Description: On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
Study NCT02863731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating working postures, second day
Description: On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
Study NCT02000596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Pertuzumab
Study NCT02000596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal Therapy with Anastrozole and Fulvestrant
Description: Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
Study NCT01246596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental root planing
Description: The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
Study NCT02461134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod
Description: Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
Study NCT02751853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conductance catheter
Description: Continuous online measurements of left ventricular pressure and volume using conductance catheters
Study NCT02751853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conductance catheter
Description: Continuous online measurements of left ventricular pressure and volume using conductance catheters
Study NCT03791814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Patients screened as HCV positive will receive Zepatier for 12 weeks.
Study NCT02243995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Study NCT02243995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Study NCT01764906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novosis
Study NCT02000596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Eribulin
Study NCT00201968 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compex Motion Stimulator
Description: Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
Study NCT00201968 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compex Motion Stimulator
Description: Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
Study NCT00201968 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Exercise
Description: An aerobic and resistance training program.
Study NCT02080351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task
Study NCT01825642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve-sparing radical prostatectomy
Study NCT01825642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: seminal vesicle-sparing radical prostatectomy
Study NCT02614391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active distraction using a tablet
Description: Playing a videogame using a computer tablet
Study NCT02614391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive distraction
Description: A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
Study NCT02423304 — intervention group
Intervention type: GENETIC
Intervention: blood samples collected from all patients
Description: blood samples collected from brachial pluxes
Study NCT00565591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol sulfate
Description: Single dose dry powder by inhalation
Study NCT00827684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT00827684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT00827684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Study NCT03034460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5024 1% cream
Description: 500 µL on half-face, five days a week during 6 weeks
Study NCT03034460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD5024 cream placebo
Description: 500 µL on half-face, five days a week during 6 weeks
Study NCT03034460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD0271/CD1579 gel
Description: 500 µL on half-face, five days a week during 6 weeks
Study NCT03034460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD0271/CD1579 gel placebo
Description: 500 µL on half-face, five days a week during 6 weeks
Study NCT00745199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cromolyn sodium
Description: oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks